('sarscov2', 30);('covid19', 15);('january', 14);('cri', 14);('omicron ba1', 13);('figure', 13);('voc', 11);('netherlands', 9);('jan', 9);('jul', 8);('oct', 8);('supplementary materials', 8);('vocs', 7);('february', 7);('google', 5);('delta omicron', 5);('supplementary', 5);('van der', 5);('dutch', 4);('apr', 4);('nature communications', 4);('delta', 3);('firstly', 3);('thirdly', 3);('quantilesmodel meandata', 3);('1data 3alpha', 3);('credible intervals', 3);('a7', 3);('omicron', 3);('2020jul 2020oct 2020jan 2021apr 2021jul 2021oct 2021jan', 3);('cri model mean datafeb', 3);('27mar 12mar 26apr 09apr', 3);('materials', 3);('age group', 3);('april', 3);('susceptible individuals', 3);('lancet', 3);('substantial feedback', 3);('columbia', 2);('center health', 2);('ci', 2);('medical center', 2);('understanding', 2);('ba1', 2);('poor predictor', 2);('delta omicron ba1', 2);('secondly', 2);('nether', 2);('ensemble adjustment', 2);('mobility data', 2);('themodel', 2);('estimated', 2);('national institute', 2);('rivm dashboard', 2);('parameter', 2);('january31', 2);('october', 2);('omicronba1', 2);('2020jun 2021jan', 2);('reported', 2);('agespecic', 2);('national seroprevalence', 2);('hospitalizationsfigure', 2);('age', 2);('across', 2);('true parameters', 2);('seroprevalence estimates', 2);('september', 2);('june', 2);('overview', 2);('rivm', 2);('old kk', 2);('s2', 2);('disease', 2);('figures', 2);('march', 2);('githubrepository', 2);('github', 2);('klis', 2);('public health', 2);('bmc', 2);('national academy', 2);('epidemiology', 2);('centre disease prevention', 2);('ob aa', 2);('arxiv221213470v1 physicssocph', 1);('dec', 1);('2022agespecic transmission dynamics', 1);('th e rst twoyears pandemicotilia', 1);('boldea phd1 amir alipoor msc1 sen pei phd2 jerey shaman phd23 gannarozhnova phd4561department econometrics center tilburg', 1);('economics', 1);('tilburg', 1);('tilburg netherlands2department environmental', 1);('mailman', 1);('ublic health', 1);('columbiauniversity', 1);('york usa3columbia climate', 1);('york usa4julius', 1);('primary care', 1);('medic', 1);('utrecht utrechtuniversity utrecht netherlands5bioisibiosystems integrative', 1);('faculdade', 1);('universidade', 1);('lisbon portugal6center complex systems studies ccss utrecht', 1);('utrecht netherlandsdecember', 1);('ganna rozhnovajulius', 1);('primary careuniversity', 1);('utrechtpo', 1);('utrecht netherlandsemailgrozhnovaumcutrechtnl', 1);('otilia boldeadepartment econometrics centertilburg', 1);('economics management tilburg univer', 1);('sitypo box', 1);('tilburg netherlandsemail', 1);('oboldeatilburguniversityedu phone', 1);('pandemic manifest', 1);('multiple waves', 1);('complexinteractions variants concern nonpharmaceut ical interventions immunological landscapeof population', 1);('agespecic epide miology', 1);('throughoutthe pandemic', 1);('policy decisions', 1);('approachto reconstruct burden', 1);('true infections hospital', 1);('missions children adolescents adults overthe', 1);('variants wildtype', 1);('alpha delta', 1);('years thepandemic', 1);('example nd', 1);('cases considerableunderestimate', 1);('true infect ion burden', 1);('diersby age contribution children adolescents tota l infection hospitalization burden increasedwith', 1);('successive variants', 1);('allinfections primary infections', 1);('naive indi viduals', 1);('periodsprimary infections', 1);('common children', 1);('r adults', 1);('reinfections orbreakthrough infections approach', 1);('unders tand agespecic epidemiology successivewaves countries random community surveys unc', 1);('dynamics absentbut', 1);('basic surveillance statistics data', 1);('pandemic dynamics', 1);('complex spatiotemporalpattern multiplewaves', 1);('dierences agespecic burden conrm', 1);('cases hospitalizations', 1);('anotableexampleistheagedistributionofreportedcaseswithmuchlo', 1);('european countries', 1);('rst wave wildtype variant thespike infections', 1);('variant concern', 1);('agespecic epidemiology', 1);('public health policy instance information inf ection burden varies age time andthe contribution dierent age groups transmission', 1);('nonpharmaceutical interventions 812like school', 1);('understanding agespecic hospitalization burden 14underpins prioritization vaccination', 1);('surveillance andserological surveys', 1);('full reconstruction ages pecic burden infections hospitalizations acountry', 1);('cases agespecic', 1);('dueto peculiarities surveillance systems', 1);('policies var', 1);('ages time', 1);('fact coupledwith evidence ofasymptomaticin fection', 1);('undermines abilityofsurveillanceto capturethe trueburden ofinfections amongdierent agegrou ps', 1);('representative serological surveys', 1);('information subpopulationscarry antibodies', 1);('characteriz eprior infection burden', 1);('due to2the', 1);('immunity vaccination infection immunolog ical landscape population', 1);('implementing', 1);('representative serosurveys', 1);('popula tion immunity amongdierent age groups', 1);('inf ections vaccination', 1);('additional factors', 1);('vo cs', 1);('nonpharmaceutical interventions812 changes population immunity vaccination infection easonality transmission 2325complicate estimation agespecic', 1);('important insights temporal cha nges epidemiology', 1);('inspecic countries', 1);('available evidence', 1);('studies reconstruct agespecic epidemiology', 1);('tospecic periods pandemic rst wave', 1);('periods dominance', 1);('alpha', 1);('anddelta variants', 1);('data accumulate formalevaluations basedon mathematical odels calibratedto dierenttypes observational data', 1);('burden infections hos pitalizationsover', 1);('long periods timehere reconstructthe epidemiologyofsarscov2', 1);('landsoverthe rst 23months ofthe pandemic aperiod', 1);('alpha delta omicron ba1', 1);('n age', 1);('transmission model', 1);('variousdata sourcessee', 1);('supplementary mat', 1);('ourtting', 1);('bayesianevidencesynthesis', 1);('kalman', 1);('surveillance andnational statistics data', 1);('available individual countries hospital admissions serological surveys', 1);('pcrtesting', 1);('data genetic', 1);('data vaccination coveragedata socia l contact matrices demographic data', 1);('regional trainand', 1);('exampleto account control measures', 1);('elementary se condary schoolchildren versus rest population', 1);('agedependent transmission eects', 1);('young children0', 1);('old adolescents', 1);('old adults abo', 1);('current knowledge', 1);('w hich suggests', 1);('immunity infectionor vaccination', 1);('potential changes susceptibility infectivity severity infections breakthroughinfections', 1);('seasonality transmission', 1);('regional stratication', 1);('provinces assumption', 1);('infection maytravel infect', 1);('susceptible individuals provinces', 1);('infectionstay province origin', 1);('previous', 1);('epidem ic models transmission dynamics coupledacross locations', 1);('identiability epidemiological para meters 27453apr', 1);('hospitalizations', 1);('crimodel meandata', 1);('1data 2alpha', 1);('delta omicron totalapr', 1);('adultsapr', 1);('2022051015202530hospitalizations 1day', 1);('adolescentsapr', 1);('delta omicron childrenfigure', 1);('hospital admissions total agespecic', 1);('national daily hospital admissions inadults b adolescents c children', 1);('dultspink adolescents turquoise children', 1);('yellow ages p urple', 1);('regions correspond toposterior', 1);('posterior ensemble values', 1);('thedots', 1);('hospital admission data', 1);('dat', 1);('intensive careevaluation', 1);('hea', 1);('environment rivm data', 1);('table 1and', 1);('solidvertical lines', 1);('samples genetic variant datarespectivelyresultstimedependent burden hospital admissionsour parsimonious model', 1);('robust estimation key timevar', 1);('epidemiological parameters compatiblewith', 1);('national regional epidemiology', 1);('pre po stvaccination periods', 1);('supplementarytables a1a6 figures a1a4', 1);('ident iability sensitivity analyses', 1);('national regionalhospital admissions', 1);('young children adolescentsand adults allwavesthat occurredfromthe rst ocialcaseon', 1);('february27', 1);('supplementaryfigures a5a7', 1);('national level total', 1);('nu mber hospital admissions', 1);('cri8272986151 supplementary', 1);('wave wildtype', 1);('alpha delta omicronba1', 1);('end study period', 1);('onset vacc ination program', 1);('pattern ofhospital admissions adults', 1);('mirrors total', 1);('national dmissions', 1);('probability ofclinical disease hospitalization subpopulation', 1);('dolescents children', 1);('figure1b', 1);('genetic variant data', 1);('frequencythe burden hospital admissions adults', 1);('linewith expansion primary vaccination series rst booster campaign', 1);('a7the', 1);('number hospital admissions', 1);('p eriod', 1);('picture dierent adolescents children thehospitalization burden', 1);('hospital admissions', 1);('group demonstratea', 1);('cumulative meannumber hospital admissions', 1);('large st', 1);('omicron ba1 delta', 1);('258693timedependent burden', 1);('cases seroprevalenc ethe model reproduces agespecic seroprevalence', 1);('bd', 1);('supplementary figures a8a16', 1);('context study seroprevalence thefraction population haveantibodies', 1);('due infectio n level seroprevalenceis', 1);('fast antibodies decay', 1);('fast new infections', 1);('national seropre', 1);('increasedin age groupsreaching84', 1);('adolesce nts', 1);('a8', 1);('contrast magnitude th e rstwave hospital admissions spring', 1);('period overall', 1);('amongchildren adolescents insets', 1);('throughout', 1);('study period', 1);('nextve waves', 1);('adults end', 1);('fig', 1);('ure2b pattern', 1);('similar adolescents', 1);('rst waves', 1);('age grou p', 1);('andseventh waves skyrocketingfrom', 1);('ado lescents', 1);('2c caseswere', 1);('children adults', 1);('wave ie', 1);('day peak case', 1);('children muc h', 1);('adults rest of5sep 2020jun 2021jan 20220020406081fraction', 1);('seropositive', 1);('criadults meandatasep', 1);('criadolescents meandatasep', 1);('crichildren meandataa seroprevalenceapr', 1);('cases adultsapr', 1);('cases adolescentsapr', 1);('delta omicron cases childrenfigure', 1);('cases adults b adolescents c children', 1);('inset', 1);('low case', 1);('lines repres ent', 1);('means adults pinkadolescents turquoise children', 1);('r egions correspond posterior', 1);('posterior e nsemble values', 1);('black dots areseroprevalence', 1);('bcd', 1);('table 1andsupplementary', 1);('solid vertical lines', 1);('samples data', 1);('comparison th e scale yaxis', 1);('bcanddwildtype alpha delta omicron002040608 fraction', 1);('reportedadults unreportedadolescents reportedadolescents unreportedchildren reportedchildren unreporteda infectionswildtype alpha delta omicron0020406081fraction', 1);('total infections hospital admissions', 1);('voc agespecicfraction', 1);('cases total', 1);('national infections hospital admissions', 1);('bduring voc', 1);('black lines', 1);('means nd', 1);('from300 posterior ensemble values6the study period', 1);('cases adolescents child ren', 1);('burden infections subpopulat ions', 1);('period achange agespecic distribution total', 1);('national cases whic h', 1);('belowage distribution total infections hospital admissio ns', 1);('vocour', 1);('model estimates temporal changes agespecic contac rates result', 1);('control measuressupplementary', 1);('w ith', 1);('mobility patterns', 1);('estimation agesp ecic distribution', 1);('unreportedcases total', 1);('national infections', 1);('figur', 1);('supplementary tables a9a10the', 1);('fraction total infections children', 1);('n ational infections light', 1);('wildtype period 129in', 1);('omicr ba1', 1);('contribution total infe ctions', 1);('foradolescents light', 1);('dark turquoise', 1);('betwee n', 1);('national infections forthe wildtype', 1);('majority f cases adolescents reportedto surveillance', 1);('infectio ns', 1);('contributionof adults total infections light', 1);('f rom', 1);('study periodwhile fraction', 1);('adult cases', 1);('wildtype period to325', 1);('period terms agespecic co ntribution total hospital admissions pervoc adult population', 1);('minor fraction hospitaladmissions', 1);('children adolescents circula tion', 1);('delta omicron ba1 figure', 1);('a11wildtype alpha delta omicron000501015020250303504fraction', 1);('ageadults primaryadults breakthrough reinfectionsadolescents primaryadolescents breakthrough reinfectionschildren primarychildren reinfectionsa', 1);('infectionswildtype alpha delta omicron0051152253hospitalized', 1);('individuals ageb', 1);('burden', 1);('stratication immune status', 1);('voc fraction', 1);('primary breakthroughinfections reinfections total population age grou p b hospital admissions primary andbreakthrough infections reinfections', 1);('individuals eac h age group', 1);('black lines showthe', 1);('semble values7agespecic burden stratication immune status', 1);('vocwe', 1);('agespecic burden total infections nd hospital admissions', 1);('immune statusand period', 1);('voc figure', 1);('supplementary tables a12a13', 1);('infe ctions fullysusceptiblenaiveindividualsprimaryinfectionsfrominfectionsin individualswhowerevaccinatedbreakthroughinfections', 1);('immunity primary infection reinfections', 1);('figure4a', 1);('hospital admission burden', 1);('hospital admissions primary infection versus fter reinfection breakthrough infection despitevaccination', 1);('primary infection wildtype', 1);('alph', 1);('reinfectionsor breakthrough infections', 1);('adults f periods', 1);('periods reinfections b reakthrough infections', 1);('primary infectionswere', 1);('adults period', 1);('simila', 1);('r dynamics', 1);('burdenof hospital admissions adults', 1);('hospital dmissions', 1);('delta omicron ba1breakthrough', 1);('due primary infec tions variants', 1);('4b stress thatlarger hospitalization burden adults', 1);('breakthroug h infectionsreinfections primaryinfections', 1);('periods consequence high vaccination coverage adults whilethe hospitalization probability vaccination', 1);('infection v ery', 1);('adults withoutany immunity extreme case', 1);('adult populat ion hospitalization burden', 1);('breakthrough infections', 1);('sma ller burden', 1);('beginning pandemic burden primar infections adolescents turquoise barswas', 1);('adults wildtype', 1);('adults primary infections inadolescents', 1);('common breakthrough infections r einfections', 1);('delta omicron ba1vocs', 1);('vaccination schedulefor adolescents burden adolescents', 1);('high durin g', 1);('wave estimated436 adolescents', 1);('young child ren', 1);('vaccination burdenin group', 1);('due primary infection', 1);('slight increaseof hospitalizations', 1);('4aandbparameter identiability sensitivity analysesthe posterior distribution parameters', 1);('rst wave', 1);('data informative', 1);('model parame ters', 1);('system identiability inthe rst wave', 1);('synthetic outbreak', 1);('infection hospitalizationdata', 1);('similar trends', 1);('original data assess parameter identiability rst wave considered8higher', 1);('case detection rates par ameter combination', 1);('synthetic outbreakswere', 1);('data reestimate th e model parameters', 1);('ge posterior', 1);('densities dierenceswere', 1);('section 62sensitivity analyses', 1);('model parameters th', 1);('results wer e', 1);('v alues', 1);('native calibrationsdiscussionwe', 1);('approach reconstru ct agespecic epidemiology', 1);('complex interac tion', 1);('nonpharmaceutical interventions immunological landscape population st udy', 1);('insights changes inthe agespecic burden infections hospitalizations sev', 1);('waves dierent', 1);('rst twoyears pandemic', 1);('netherlands firstly', 1);('considerable underestimateof total infections majority infections age groups r', 1);('overall improvement case', 1);('cases gener ally', 1);('true incidence', 1);('contribution children adolescentsto total infection hospitalization burden', 1);('succes sive', 1);('period increase demonstrates', 1);('substantial burdens', 1);('olescents children', 1);('additional pressureon healthcare systems', 1);('pattern infections hospitalizations immunestatus age', 1);('infections primary inf ections', 1);('naive individuals', 1);('howeverduring delta omicron ba1', 1);('periods primary infections com mon children', 1);('early vaccination rollout', 1);('hat age groups relativelyrare adults', 1);('reinfections breakthrou gh infectionsa', 1);('identie case data', 1);('uk', 1);('howeverunlike', 1);('wav e study', 1);('primaryinfections versus reinfections breakthrough infections es', 1);('periodthe discrepancy', 1);('th e population stratication', 1);('studyfor computational eciency model distinguishes', 1);('naive indiv iduals immunity', 1);('byeither vaccine', 1);('natural infection', 1);('reinfections breakthrough infections groupedto knowledge rst', 1);('comprehensive applicatio n', 1);('estimates infection h ospitalization burden age region', 1);('vocand', 1);('immune status', 1);('waves rst', 1);('pandem ic yearsin', 1);('case framewor k', 1);('countries giventhe', 1);('common surveillance', 1);('national statistics data', 1);('compared', 1);('model contacts', 1);('elementary schools', 1);('secondary schools rest thepopulation', 1);('enable reliable disentanglement roles child ren adolescents adults transmissionwe estimate contact changes', 1);('due nonpharmaceutical interve ntions', 1);('school environment', 1);('onproxy mobility measures', 1);('train mobility transit stations proxy bserve thatmost measures', 1);('ocial implem entation', 1);('estimate speed ofbehavioral changes number agespecic contacts', 1);('er intervention', 1);('studies eg', 1);('constant ver timeretrospective analysesof impact transmission burden dierent age groups vaccination boostingand nonpharmaceutical interventions', 1);('secondary schoolchildren rest thepopulation focus', 1);('future workour model', 1);('regional hospital admissions', 1);('wend', 1);('data sources', 1);('moveme nt', 1);('infection inference method nationalseroprevalence data', 1);('secondary role', 1);('tr ansmission dynamics', 1);('due low frequencyof serosurveys ie', 1);('months case fact', 1);('transmissionmodel stochastic', 1);('applicable countries whereseroprevalence estimates', 1);('freque ncy', 1);('incorporation', 1);('measurements sewage w ater', 1);('apparent ie', 1);('drastic changes', 1);('surv eillance', 1);('european countries includingthe', 1);('projections f transmission dynamics largescale', 1);('pcrtestingstopped ourmodelcouldalsobeextendedtoquantifysar scov2infectionandcovid19hospitalizationburdens', 1);('vulnerable populations', 1);('chronic condition', 1);('themour model limitations', 1);('children adolescen ts', 1);('early stages pandemic makesthe identication agespecic parameters ie susceptibilit', 1);('initial period', 1);('individuals observe g ood identication agespecic', 1);('age categories', 1);('straightforward stratify adultpopulation', 1);('age categories relevant', 1);('bu rden', 1);('means metapopulation model mobility ay', 1);('case detection ratesand data', 1);('estimate agespecic para meters', 1);('choice stratication into10primary versus breakthrough infections reinfections', 1);('time period', 1);('large proportion ofthe population', 1);('sarscov2 sars cov2', 1);('transitions pandemicity toendemicity primary infections', 1);('young children', 1);('population 2958for', 1);('periods model', 1);('dierentiate betwe', 1);('immunity classes individualswith primary vaccination series', 1);('various boosters', 1);('infectio ns hybrid immunity 59in conclusion', 1);('transmissionmode l estimates agespecic epidemiologyof', 1);('changes time approach relevant co untries random community', 1);('absent basic surve illance statistics data', 1);('thendings', 1);('study burden infections hospitalization children adolescents adults areimportant', 1);('public health policy nonpharmaceutical terventions vaccinationmethodsoverviewthe transmission model', 1);('surveillance nationa l statistics data', 1);('pcr', 1);('data hospitaladmissions serological surveys demographic data', 1);('regional tra', 1);('mobility data vaccination coveragedata genetic', 1);('social contact matrices', 1);('themodel age', 1);('case ication data period', 1);('ii ageand provincestratiedcov', 1);('id19hospital', 1);('admissiondata forthe periodand iii crosssectional', 1);('national seroprevalence data', 1);('june4 september', 1);('median dates', 1);('additional', 1);('data model input ivpopulation age province', 1);('commut ers', 1);('national train data period', 1);('full v accinations', 1);('province age category duringthe period', 1);('vii wee', 1);('period fromnovember', 1);('weekly genetic', 1);('data period', 1);('december', 1);('ix school nonschool contact matrices', 1);('surveys pandemicapril', 1);('model analyses', 1);('mat lab', 1);('versions 2021a 2022a', 1);('datacleaning', 1);('stata', 1);('se v16 code', 1);('mod el', 1);('entire sample period runs', 1);('windows', 1);('dell', 1);('intel cor', 1);('e i5 processor', 1);('parallelizationdatatable1gives overview data notation sources details n dataset', 1);('foruse model', 1);('supplementary materials sec', 1);('model ttingdata', 1);('notationsourcepopulation', 1);('age group k', 1);('ik cbs', 1);('2020in province httpsopendatacbsnlstatlineportalhtmllaen', 1);('inewobsikt rivm dashboardhttpsdatarivmnlcovid19covid19casuslandel', 1);('hospital admissionsdataset', 1);('hnewobsik1t rivmdatafromfebruary272020untilseptember302021dataset', 1);('hnewobsi2t rivm dashboard october', 1);('onwardhttpsdatarivmnlcovid19covid19ziekenhuisop namescsvhttpsdatarivmnlcovid19covid19ziekenhuisop namestm03102021csvdataset', 1);('hnewobsk3t rivm dashboard october', 1);('onwardhttpsdatarivmnlcovid19covid19ziekenhuisi copnamesperleeftijdsgroepcsvhttpsdatarivmnlcovid19covid19ziekenhuisi copnamesperleeftijdsgroeptm03102021csvseroprevalence data', 1);('rivm pienter corona', 1);('andserosurvey rounds h', 1);('httpswwwrivmnlenpientercoronastudyresultsmedian inclusion time tserhfraction seropositive serhksample size nhktrain mobility', 1);('mijt', 1);('dutch railways ns', 1);('databetween provinces iandj', 1);('mobility datafraction commuters wij cbs year 2019from province jtoi httpswwwcbsnlnlnlcijfersdetail83628nedgoogle mobility yg httpswwwgooglecomcovid19mobilityfrom', 1);('vikt', 1);('rivm dashboardhttpsdatarivmnlcovid19covid19vaccinatiegr', 1);('datahttpswwwrivmnlencovid19vaccinationarchive covid19vaccinationfigures2021booster transition function gbktk', 1);('datahttpswwwrivmnlencovid19vaccinationarchive covid19vaccinationfigures2022variants transition function gt', 1);('datahttpsdatarivmnlcovid19covid19variantencs vcontact matrices', 1);('4261elementary school contacts cikkest', 1);('additional information school closures vacationssecondary school contacts cikksst', 1);('additional information school closures', 1);('contacts crkkr', 1);('61rrefers survey roundsnonschool contacts crkknsr', 1);('4261rrefers survey roundsthe indices ij', 1);('indices kkdenote age groupnamelykk', 1);('children09 years', 1);('old index h', 1);('denotes serosurvey round index lodenotes', 1);('alphadelta omicron vocs12transmission', 1);('stochastic compartmental metapopulation model', 1);('transmission population', 1);('province disease status nd age schematic', 1);('disease mobilitydynamics', 1);('main model parameters hown', 1);('5disease dynamics', 1);('naivesusceptible individuals', 1);('s1', 1);('e1with', 1);('agespecic force infection', 1);('averagelatent period', 1);('individuals becomeinfectious primary infection', 1);('i1', 1);('new infectious cases agespecic frac tionis reportedto surveillance', 1);('ir1', 1);('iu1', 1);('infectious individuals', 1);('r1', 1);('average infectious period', 1);('h1', 1);('agespecic rate', 1);('hospitalized', 1);('anaverage agespecic hospitalization period', 1);('primary infection individuals', 1);('similar tothat', 1);('susceptible dividuals', 1);('agespecicforce infection', 1);('age specic rate', 1);('theimmunity reinfection', 1);('upon', 1);('immunity reinfection individuals returnto', 1);('susceptible compartment', 1);('s2 vaccination', 1);('individuals agespecic rate voccurs inall disease stages', 1);('infectio n hospitalization', 1);('susceptible individuals vaccination individuals reco', 1);('primary infection', 1);('reinfections andbreakthrough infections', 1);('vaccination', 1);('susceptibility toreinfection breakthrough infection aects', 1);('infectivity reinfection breakthrough infection', 1);('diagram iii', 1);('hospitalization rate', 1);('er reinfection breakthrough infection2 model assumes', 1);('constant population size study pe riodmobility dynamics', 1);('themodelassumestheunreportedinfectedtravelandinfectot', 1);('susceptible individuals travel', 1);('heterogeneity population size mobility', 1);('gions assumption equips model withadditional dynamics', 1);('identication unreportedcases', 1);('case detection rate acros regions sucient', 1);('regions time', 1);('case detec tionrate', 1);('due ability test ny location', 1);('estimate model', 1);('utch provincesa', 1);('full description model model equations', 1);('section 213figure', 1);('schematic', 1);('metapopulation transmission mod ela', 1);('dynamics b', 1);('mobilitydynamics', 1);('model diagram simplicit presentation theagespecic indices', 1);('schematic14parameter inferencethe model', 1);('infection hospitalization seroprevalenc e data', 1);('kalmanlter', 1);('inference highdimensional system obser', 1);('variables andparameters', 1);('ecient way', 1);('large number f ensembles', 1);('priors allparameters state variables', 1);('stochastic version metapopulationmodel', 1);('lter updates ensemble member', 1);('means ofa', 1);('form approximation akin', 1);('normal distribution n', 1);('additional bias correction updatesare', 1);('data province neighbours', 1);('large number ofstate variables parameters', 1);('details estimation algorithm', 1);('supplementary materialsa', 1);('small number parameters', 1);('par ameters', 1);('choice ofpriors', 1);('supplementary materials sect', 1);('parameter posteriors theirtimeevolution variant periods', 1);('supplementary materialsmodel', 1);('exact calculations', 1);('supplementary materials sections', 1);('supplementary tables a9 a11a13', 1);('details', 1);('parameter identiability sensitivity alysesto verifysystem identiability forthe rstwave', 1);('param etersat estimatedposteriorsin originalsample observations', 1);('a14', 1);('onesynthetic outbreak', 1);('model parameters synthetic data addition', 1);('thesynthetic data', 1);('similar original data', 1);('ur method', 1);('andmodel seroprevalence', 1);('a15 figures a17a20', 1);('assessparameter identiability rst wave', 1);('pa rameter congurations describedabove case detection rates', 1);('equal original sample post erior', 1);('case detection rates andiii case detection rates', 1);('ii un til', 1);('synthetic outbreaks', 1);('w hich', 1);('data reestimate modelparameters', 1);('model congurations', 1);('range theposterior', 1);('densities dierences', 1);('sup', 1);('figures a21a23', 1);('case iii lter', 1);('increase c ase detection rates', 1);('suggests changes', 1);('capacity recommendations unmodelled15parameter changes', 1);('model inference tech nique', 1);('uncertainty whendata', 1);('supplementary figure a24for', 1);('sensitivity analyses', 1);('model e ntire sample period', 1);('serosurveydata ii', 1);('rates primary inf ection iii', 1);('period primary breakthrough infectionreinfection ivwith', 1);('cases exceptiii calibrations lead', 1);('available seroprevalen ce estimates', 1);('model estimation', 1);('tables a16a19', 1);('casesiiiiv results robust', 1);('immunity wanes aver age', 1);('months theomicron', 1);('summaryfurther information research design', 1);('nature res', 1);('reporting summary', 1);('togetherwith manuscriptdata availabilityall output datasets', 1);('acceptance manuscript', 1);('thedatasets', 1);('input study', 1);('input datasets', 1);('seroprevalence data train mobility data', 1);('available desig', 1);('acceptance manuscript requests forseroprevalence data', 1);('fiona', 1);('eric vosericvos02rivmnl', 1);('environment bilthoven netherlands', 1);('requests train mobility data', 1);('b anninga janbanningansnl', 1);('dutchrailways nederlandse spoorwegen ns', 1);('available reviewers editors', 1);('requestcode availabilityall codes', 1);('results study', 1);('repository httpsgithubcomoboldeacovidageregions', 1);('acceptance manuscript codes', 1);('areavailable reviewers editors', 1);('request16references1 world health organization', 1);('coronavirus covid19 dashboard', 1);('available fromhttpscovid19whoint', 1);('variation covid19', 1);('infectionfatality ratio age time geography prevaccine era asystematic analysis', 1);('odriscoll dos santos gr wang', 1);('cummings dat azman pair', 1);('mortalityand immunity patterns', 1);('sarscov2 nature', 1);('coronavirus', 1);('available httpscoronadashboardgovernmentnl', 1);('koelle k martin antia r lopman', 1);('dean', 1);('epide miology', 1);('sarscov2 science2022375658511161121', 1);('monod blenkinsop xi x hebert bershan tietze', 1);('groups sustain resurgingcovid19 epidemics', 1);('eabe8372 doi101126scienceabe83727', 1);('davies ng klepac p liu prem k jit pearson cab', 1);('aged', 1);('ependent eects transmissionand control', 1);('nature medicine', 1);('perra n nonpharmaceutical', 1);('covid', 1);('pandemic review', 1);('physics reports2021913152', 1);('liu morgenstern', 1);('kelly j lowe r', 1);('ccw jit', 1);('impact nonpharmaceutical interventions', 1);('countries territ ories', 1);('medicine 20211914040doi101186s1291602001872810', 1);('sharma mindermann rogerssmith', 1);('leech g snodin', 1);('eectiveness government interventions resurgence', 1);('covid19 europe nature', 1);('communications202112158205820 doi101038s4146702126013411', 1);('brauner jm mindermann sharma johnston salvatier j gaven', 1);('inferringthe', 1);('eectiveness government interventions', 1);('science 20213716531eabd9338doi101126scienceabd933812', 1);('li campbell h kulkarni harpur nundy wang x', 1);('temporal association introducingand', 1);('nonpharmaceutical interventions', 1);('reproduction number', 1);('r sarscov2amodellingstudy', 1);('thelancetinfectiousdise', 1);('rozhnovag', 1);('dorp ch bruijningverhagenp bootsmam', 1);('wijgert j bonten', 1);('modelbasedevaluation', 1);('measures contro l', 1);('flook jackson', 1);('vasileiou e simpson cr muckian md agrawal u', 1);('informing', 1);('public healthresponse', 1);('systematic review risk factors dis', 1);('severity mortality', 1);('bubar km reinholt k kissler sm lipsitch cobey grad yh', 1);('modelinformed covid19', 1);('vaccineprioritization strategies age serostatus science', 1);('matrajt', 1);('eaton j leung brown er vaccine', 1);('optimization fo r', 1);('vaccinate rst', 1);('scienceadvances', 1);('202176eabf1374 doi101126sciadvabf137417', 1);('sah p fitzpatrick mc zimmer cf abdollahi e judenkelly', 1);('mog', 1);('sm', 1);('asymptomatic sarscov2', 1);('infection systematic review metaanalysis', 1);('proceedin', 1);('sciences202111834e2109229118', 1);('oce', 1);('statistics coronavirus covid19 infec', 1);('survey uk', 1);('available fromhttpswwwonsgovuksurveysinformationforhouseh oldsandindividualshouseholdandindividualsurveysco vid19infectionsurvey', 1);('shioda k lau msy kraay anm nelson kn siegler aj sullivan ps', 1);('estimating cumulative incidence sarscov2 infection infection fatality ratio', 1);('l ight', 1);('waning antibodies epidemiology202132420 hoz', 1);('n paireau j lapidus n tran kiem', 1);('salje h severi g', 1);('monitoring', 1);('proportion thepopulation', 1);('hospitalisa tion serological data modellingstudy', 1);('public health 202166e408e415 doi101016', 1);('s246826672100064521 milne g hames scotton', 1);('gent n johnsen anderson rm', 1);('infection vaccinationagainst', 1);('lancet respirator medicine', 1);('202191214501466doi101016s221326002100407022 world health organization', 1);('tracking sarscov2', 1);('available fromhttpswwwwhointenactivitiestrackingsarscov 2variants', 1);('townsend jp lamb ad hassler hb sah p nishio aa nguyen', 1);('c e', 1);('projectingthe', 1);('seasonalityof endemiccovid19 medrxiv 2022doi101101202201262226990524', 1);('kissler sm tedijanto', 1);('goldstein e grad yh lipsitch projec', 1);('transmission dynamics', 1);('postpandemic period science', 1);('neher ra dyrdakr druelle v hodcroft eb albert j potentia', 1);('med wkly', 1);('viana j', 1);('dorp ch nunes gomes mc', 1);('boven kretzsc', 1);('controlling', 1);('vaccination rollout', 1);('pei yamana tk kandula galanti shaman j burden', 1);('c haracteristics', 1);('covid19 unitedstates', 1);('nature', 1);('saadroy cm wagner ce baker morris', 1);('farrar j grah al', 1);('immune', 1);('life historyvaccination dynamics', 1);('year science 20203706518811818doi101126scienceabd734329', 1);('lavine js bjornstad antia r immunological', 1);('characterist ics', 1);('toendemicity science', 1);('doi101126scienc eabe652230', 1);('sonabend r whittles lk imai n perezguzman pn knock es rawson', 1);('nonpharmaceuticalinterventions', 1);('delta variant', 1);('en', 1);('gland mathematical', 1);('dekker mm coeng le pijpers fp panja', 1);('vlas sj reducin', 1);('g societal impacts', 1);('interventions subnational implementation medrxiv 2022doi10', 1);('gatto bertuzzo e mari', 1);('miccoli carraro', 1);('casagrand r', 1);('spread', 1);('italy eects', 1);('emergency containment measures', 1);('national academy ofsciences', 1);('bertuzzo e mari', 1);('pasetto miccoli casagrandi r gatt', 1);('italy', 1);('implications relaxationof connement measures', 1);('giordano g blanchini', 1);('bruno r colaneri p di filippo di matt', 1);('modelling covid19', 1);('epidemic implementation populationwide interventions', 1);('ita', 1);('nature med', 1);('bosetti p tran kiem', 1);('andronico colizza v yazdanpanah fontanet', 1);('francebmc medicine', 1);('presanis de angelis goubar gill ades ae bayesian', 1);('ev idence synthesis transmission', 1);('dynamic model', 1);('hiv', 1);('men sex men', 1);('biost', 1);('atistics 2011124666681doi101093biostatisticskxr00637', 1);('birrell pj ketsetzis g gay nj cooper bs presanis harris rj', 1);('bayesian', 1);('ah1n1pdm', 1);('london proceedings', 1);('sciences2011108451823818243', 1);('rozhnova g kretzschmar', 1);('f van', 1);('baarle korn', 1);('vossen ac', 1);('shortand', 1);('longterm impact vaccination cytomegalovirus mod', 1);('bmc medicine', 1);('anderson jl ensemble adjustment kalman filter data', 1);('similation monthly', 1);('weather review2001129122884', 1);('doi101175152004932001129288 4aeakff20co240', 1);('pei kandula shaman j dierential', 1);('eects intervention timing', 1);('unitedstates', 1);('advances', 1);('2020649eabd6370 doi101126sc iadvabd637041', 1);('mossong j hens n jit beutels p auranen k mikolajczyk r', 1);('social contacts', 1);('patternsrelevantto spreadofinfectious diseases', 1);('plosmedicine', 1);('mistry litvinova pastore piontti chinazzi fumanelli', 1);('gomes mfc', 1);('inferringhighresolution', 1);('patterns disease', 1);('goldstein e lipsitch cevik', 1);('eect age trans mission', 1);('householdsschools community journal', 1);('infectious diseases', 1);('viner rm mytton ot bonell', 1);('melendeztorresgj ward j hu', 1);('dson l', 1);('susceptibility sarscov2infection', 1);('adolescents compared adults', 1);('review metaanalysisjama pediatrics', 1);('doi101001jamapediatric s2020457345', 1);('li r pei chen', 1);('b song', 1);('zhang yang', 1);('substantial', 1);('infection facilitates', 1);('rapid dissemination novel coronavirus', 1);('science 20203686490489493doi101126scienceabb322146', 1);('sarsc', 1);('ov2 variants concern', 1);('available httpswwwecdceuropaeuencovid19variantscon cern47', 1);('keeling mj patterns', 1);('infection reinfection', 1);('arscov2 england', 1);('theoreticalbiology5561112992048 miura', 1);('leung ky klinkenberg ainslie kec wallinga j optimal', 1);('va ccine allocation', 1);('covid19 netherlands', 1);('datadriven prioritization', 1);('plos computat', 1);('biology', 1);('ainslie kec backer j', 1);('boer p', 1);('hoek aj klinkenberg alte hk', 1);('impact vaccinatingadolescents children', 1);('disease outcomes medrxiv 2021doi101101202110212126531850 van', 1);('boven hetebrij wa swart nagelkerkee', 1);('bee', 1);('rfhj stouten', 1);('modelling', 1);('netherlands august', 1);('2020febru ary', 1);('nationwide sewagesurveillance program medrxiv 2022doi10110120220525222755', 1);('schootuiterkampmhhg', 1);('osgensmheesterbeekhvanderh ofstadrlitvakn', 1);('theroleofinterregionalmobility', 1);('transmission journal', 1);('roya', 1);('l society', 1);('interface', 1);('hendriks boon steenbakkers', 1);('heesterbe', 1);('hofstad r', 1);('tradeosbetween', 1);('mobility restrictions transmission', 1);('sarscov2 jou', 1);('royal society', 1);('interface20211817520200936', 1);('vlas sj coeng le achieving', 1);('herd immunity', 1);('country level exit strategyof', 1);('scientic', 1);('brandspcojaljazizarwerev okiroeakombeiket', 1);('co vid19transmissiondynamicsunderlyingepidemic', 1);('kenya', 1);('doi101 126scienceabk041455', 1);('kishore n taylor ar jacob pe vembar n cohen buckee co', 1);('evaluating', 1);('reliability mobilitymetrics aggregatedmobile phone data proxies', 1);('sarsco v2', 1);('usa', 1);('lancet digital', 1);('health 202241e27e36 doi10', 1);('boldea corneamadeiraa madeira j disentangling', 1);('eect measures variants vaccines', 1);('sarscov2 infections england', 1);('dynamic intensity model medrxiv', 1);('core', 1);('pr otocol', 1);('ecdc', 1);('vaccine eectiveness hospitalisation', 1);('se', 1);('acute respiratory infection', 1);('available fromhttpswwwecdceuropaeuenpublicationsdatacor eprotocolecdcstudiescovid19vaccineeffectiven essagainsthospitalisation', 1);('cohen le spiro dj viboud', 1);('projecting sarscov2', 1);('tran sition pandemicity toendemicity', 1);('epidemiological', 1);('immunological considerations', 1);('plos p', 1);('athogens 2022186121doi101371journalppat10105912159', 1);('bobrovitz n ware h x li z hosseini r cao', 1);('protec', 1);('tive eectiveness', 1);('sarscov2infection', 1);('hybrid immunity', 1);('severe dis', 1);('systematic review metaregression medrxiv 2022doi101101202210022228061060', 1);('vos era', 1);('hartog g schepp rm kaaijk p', 1);('vliet j helm k', 1);('nationwide', 1);('seroprevalence ofsarscov2 identication risk factors', 1);('general popula tion', 1);('rstepidemic wave journal', 1);('community health 2020doi1 01136jech202021567861', 1);('backer', 1);('mollema', 1);('vos er klinkenberg', 1);('klis fr', 1);('impact', 1);('p atterns', 1);('crosssectional surveys', 1);('euro', 1);('li q guan x wu p wang x zhou', 1);('tong', 1);('early', 1);('transmiss ion dynamics', 1);('wuhan china', 1);('england', 1);('medicine', 1);('horta', 1);('liu j schwieg estimating', 1);('fraction unrep', 1);('infections epidemics witha', 1);('epicenter application', 1);('econom', 1);('etrics 20212201106129doi101016jjeconom202007047acknowledgementsgr', 1);('verdi', 1);('european union', 1);('views', 1);('authors ne', 1);('unionor', 1);('digital', 1);('executive agency', 1);('authority beheld', 1);('gr sp', 1);('fund c ao para', 1);('encia e', 1);('tecnologia', 1);('tilburg univer', 1);('sity fund', 1);('js sp', 1);('supportedby us', 1);('niaid', 1);('r01ai163023 cdc', 1);('contract 75d30122c142', 1);('prof marc bonten universitymedical', 1);('utrecht dr susan', 1);('van den', 1);('hof', 1);('instit', 1);('environmentprof dennis huisman erasmus', 1);('rotterdam jan ban', 1);('nederlandse spoorwegen', 1);('data study', 1);('bettina siinger tilburg', 1);('university forthe', 1);('tilburg center liss panel survey', 1);('support study', 1);('dr marino', 1);('zelst wageningenuniversity prof jaap abbring tilburg', 1);('useful discussions data availability modelling22author contributionsob', 1);('gr', 1);('important feedback authors', 1);('ob grobtained', 1);('computer c ode', 1);('sp grwrote', 1);('ob sp js ob', 1);('supplementary materialswith', 1);('partial ownership', 1);('sk analytics', 1);('competinginterestsadditional informationsupplementarymaterialscontaindetailsofthedata model infe rence systemidentiability sensitivityanalysessupplementary', 1);('figures tables supplementary materials', 1);('correspondencecorrespondence', 1);('material requests', 1);('ganna rozhnova julius', 1);('healthsciences primary care', 1);('utrecht po', 1);('utrecht netherlands', 1);('dr otilia boldea', 1);('econometrics cent er tilburgschool economics management tilburg', 1);('po', 1);('tilburg netherlands', 1);